Back to top

Analyst Blog

Zacks Equity Research

Sarepta Therapeutics (SRPT) Worth Considering: Stock Surges 18.0%

GILD BIIB SRPT

Trades from $3

Sarepta Therapeutics, Inc. (SRPT - Free Report) was a big mover last session, as its shares advanced about 18% on the day. The move came on the back of solid volume too, as far more shares changed hands than in a normal session. The uptrend is continuing for this biotechnology company, with the stock surging more than 34% in the past one-month time period.

The company has seen 6 positive revisions in the past few weeks and its earnings consensus has moved up over the past two months, suggesting that more solid trading could be ahead for SRPT. So make sure to keep an eye on this stock going forward to see if this recent jump turns into more strength down the road.

Sarepta Therapeutics currently has a Zacks Rank #3 (Hold) and its Earnings ESP is positive.

Some better performing biotechnology stocks include Affymetrix Inc. , Biogen Idec Inc. (BIIB - Free Report) and Gilead Sciences Inc. (GILD - Free Report) . All these carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

GILEAD SCIENCES (GILD) - free report >>

BIOGEN INC (BIIB) - free report >>

SAREPTA THERAP (SRPT) - free report >>